YE-NEO-001

NANT Neoepitope Yeast Vaccine · NantBioScience, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for YE-NEO-001, covering 2024-07-17 to 2024-07-17. Get the full timeline:

Most recent: Clinical Trial Update: QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. [Phase 1]

See pricing